Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin

Nature Cell Biology

Volumn 14, Issue 11, 2012, Pages 1203-1211

  Min, Lihua ^a   Ji, Yuan ^b   Bakiri, Latifa ^c   Qiu, Zhixin ^a   Cen, Jin ^a   Chen, Xiaotao ^a   Chen, Lingli ^b   Scheuch, Harald ^d   Zheng, Hai ^d   Qin, Lunxiu ^b   Zatloukal, Kurt ^e   Hui, Lijian ^a   Wagner, Erwin F ^c  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b FUDAN UNIVERSITY   (China)

^c BBVA University Institute for Economic and Social Analysis University of Alcalá   (Spain)

^d RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C FOS; PROTEIN C JUN; PROTEIN P53; SIRTUIN 6; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INHIBITION; HISTONE MODIFICATION; LIVER CANCER; LIVER CARCINOGENESIS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ANIMALS; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MALE; MICE; PROTEIN BINDING; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SIRTUINS; TRANSCRIPTION FACTOR AP-1;

ANIMALIA;

EID: 84869082071     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb2590     Document Type: Article

References (40)

1. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011
2. Gotay, C.C. Cancer prevention: major initiatives and looking into the future. Exp. Rev. Pharmacoecon Outcomes Res. 10, 143-154 (2010
3. Farazi, P.A. & DePinho, R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674-687 (2006 (Pubitemid 44286000)
4. Poon, R.T. Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge. Hepatology 54, 757-759 (2011
5. He, G. et al. Hepatocyte IKK-/NF-B inhibits tumor promotion and progres- sion by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17, 286-297 (2010
6. Takami, T. et al. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res. 67, 9844-9851 (2007 (Pubitemid 47621232)
7. Maeda, S., Kamata, H., Luo, J.L., Leffert, H. & Karin, M. IKK- couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977-990 (2005 (Pubitemid 40884391)
8. Eferl, R. & Wagner, E.F. AP-1: A double-edged sword in tumorigenesis. Nat. Rev. Cancer 3, 859-868 (2003
9. Lopez-Bergami, P., Lau, E. & Ronai, Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat. Rev. Cancer 10, 65-76 (2010
10. Lee, J.S. et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nature Med. 12, 410-416 (2006
11. Eferl, R. et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112, 181-192 (2003 (Pubitemid 36144108)
12. Hui, L., Zatloukal, K., Scheuch, H., Stepniak, E. & Wagner, E.F. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1- dependent p21 downregulation. J. Clin. Invest. 118, 3943-3953 (2008
13. Hui, L. et al. p38- suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat. Genet 39, 741-749 (2007 (Pubitemid 46848584)
14. Das, M., Garlick, D.S., Greiner, D.L. & Davis, R.J. The role of JNK in the development of hepatocellular carcinoma. Gene. Dev. 25, 634-645 (2011
15. Hasselblatt, P., Rath, M., Komnenovic, V., Zatloukal, K. & Wagner, E.F. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proc. Natl Acad. Sci. USA 104, 17105-17110 (2007 (Pubitemid 350210999)
16. Liu, P. et al. Activation of NF-B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J. Hepatol. 37, 63-71 (2002 (Pubitemid 34713056)
17. Fausto, N. & Campbell, J.S. Mouse models of hepatocellular carcinoma. Semin. Liver Dis. 30, 87-98 (2010
18. Kellendonk, C., Opherk, C., Anlag, K., Schutz, G. & Tronche, F. Hepatocyte-speci-c expression of Cre recombinase. Genesis 26, 151-153 (2000
19. Ramachandran, R. & Kakar, S. Histological patterns in drug-induced liver disease J. Clin. Pathol. 62, 481-492 (2009
20. Altieri, D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 8, 61-70 (2008
21. Kinoshita, K. et al. Adenovirus-mediated expression of BMP-7 suppresses the development of liver -brosis in rats. Gut 56, 706-714 (2007 (Pubitemid 46662939)
22. Mesri, M., Wall, N.R., Li, J., Kim, R.W. & Altieri, D.C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest. 108, 981-990 (2001 (Pubitemid 32946072)
23. Wang, R.H. et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1- associated tumorigenesis. Mol. Cell 32, 11-20 (2008
24. Kawahara, T.L. et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-B- dependent gene expression and organismal life span. Cell 136, 62-74 (2009
25. Michishita, E. et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452, 492-496 (2008 (Pubitemid 351450840)
26. Bozec, A. et al. Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature 454, 221-225 (2008 (Pubitemid 351969891)
27. Mehic, D., Bakiri, L., Ghannadan, M., Wagner, E.F. & Tschachler, E. Fos and jun proteins are speci-cally expressed during differentiation of human keratinocytes. J. Invest. Dermatol. 124, 212-220 (2005 (Pubitemid 40100971)
28. Goto, H. et al. Complex formation of Plk1 and INCENP required for metaphase-anaphase transition. Nat. Cell Biol. 8, 180-187 (2006
29. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. Hepatology 49 658-664 (2009
30. Reed, K.R. et al. A limited role for p53 in modulating the immediate phenotype of Apc loss in the intestine. BMC Cancer 8, 162 (2008
31. Christophorou, M.A., Ringshausen, I., Finch, A.J., Swigart, L.B. & Evan, G.I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214-217 (2006 (Pubitemid 44387609)
32. Feldser, D.M. et al. Stage-speci-c sensitivity to p53 restoration during lung cancer progression. Nature 468, 572-575 (2010
33. Junttila, M.R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567-571 (2010
34. Pikarsky, E. et al. NF-B functions as a tumour promoter in in-ammation-associated cancer. Nature 431, 461-466 (2004
35. Meixner, A., Karreth, F., Kenner, L., Penninger, J.M. & Wagner, E.F. Jun and JunD-dependent functions in cell proliferation and stress response. Cell. Death Differ. (2010
36. Mikula, M. et al. The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis. Oncogene 22, 6725-6738 (2003 (Pubitemid 37372213)
37. Fleischmann, A., Jochum, W., Eferl, R., Witowsky, J. & Wagner, E.F. Rhabdomyosar- coma development in mice lacking Trp53 and Fos: Tumor suppression by the Fos protooncogene. Cancer Cell 4, 477-482 (2003 (Pubitemid 38050044)
38. Montorsi, M. et al. Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 54, 2040-2044 (2007
39. Kim, H.S. et al. Hepatic-speci-c disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. 12, 224-236 (2010
40. Park, E.J. et al. Dietary and genetic obesity promote liver in-ammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010